Identificada una nueva vía de resistencia a tratamientos quimioterápicos en cáncer.

Professor of Molecular Oncology Master and renowned researcher focused on the field of cancer epigenetics, Dr. Manel Esteller, He has published an article in the journal PNAS describing as a non-coding RNA, TP53TG1, It could be key in the correct response to DNA damage promoted by p53.
In this interesting publication, Dr. Esteller y sus colaboradores describen como la metilación asociada al silenciamiento de TP53TG1 promueve una mayor agresividad en los tumores y una resistencia a los tratamientos con agentes de daños al DNA (fármacos quimioterápicos) and even drugs targeted, as is the case of PI3K and AKT inhibitors.
Under normal conditions, TP53TG1 joins the YBX1 oncoprotein and thus prevents its nuclear localization and enhance a tumor phenotype. However, TP53TG1 epigenetic inactivation in tumor cells results in the release of YBX1, favoring tumor aggressiveness and resistance to chemotherapy.
So, in this article the research group led by Dr.. Esteller suggested as TP53TG1 hypermethylation could be not only an example of tumor suppressor, but it could serve as a marker, together with the location of YBX1 chemotherapy resistance,es.